Skip to Content


Active Substance: insulin lispro
Common Name: insulin lispro
ATC Code: A10AB04
Marketing Authorisation Holder: Eli Lilly and Company Limited
Active Substance: insulin lispro
Status: Withdrawn
Authorisation Date: 1997-05-07
Therapeutic Area: Diabetes Mellitus
Pharmacotherapeutic Group: Fast acting human insulin analogue

Therapeutic Indication

For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.  Liprolog is also indicated for the initial stabilization of diabetes mellitus.  Liprolog  is a short acting insulin and may be used in conjunction with a longer acting human insulin.  Liprolog is indicated for preprandial administration.

The marketing authorisation for Liprolog has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.